CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.39
−1.77%1
Insider buys (3m)
0
Insider sells (3m)
$250.2K
Net value (3m)
+30.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jun 15, 2026 | Grais Linda · director | A-Award | 15,000 | $12 |
| Jun 15, 2026 | Moore David Scott · director | Purchase | 21,700 | $12 |
| Jun 15, 2026 | Moore David Scott · director | A-Award | 15,000 | $12 |
| Jun 15, 2026 | CLARK IAN T · director | A-Award | 15,000 | $12 |
| Jun 15, 2026 | van den Broek Richard · director | A-Award | 15,000 | $12 |
| Jun 15, 2026 | Thompson Peter A. · director, 10 percent owner: | A-Award | 15,000 | $12 |
| May 20, 2026 | MILLER RICHARD A MD · director, officer: President and CEO | Purchase | 5,000 | $12 |
| May 20, 2026 | MILLER RICHARD A MD · director, officer: President and CEO | Purchase | 1,932 | $12 |
| Apr 27, 2026 | Chan Andrew C. · director | A-Award | 30,000 | $16 |
| Jan 30, 2026 | Thompson Peter A. · director, 10 percent owner: | M-Exempt | 30,000 | $15 |
| Jan 30, 2026 | Thompson Peter A. · director, 10 percent owner: | M-Exempt | 15,000 | $2.12 |
| Dec 8, 2025 | MILLER RICHARD A MD · director, officer: President and CEO | A-Award | 1,000,000 | $8.81 |
| Dec 8, 2025 | Jones William Benton · officer: See Remarks | A-Award | 400,000 | $8.81 |
| Dec 8, 2025 | LEA LEIV · officer: Chief Financial Officer | A-Award | 400,000 | $8.81 |
| Dec 8, 2025 | Arcara Jeffrey · officer: Chief Business Officer | A-Award | 100,000 | $8.81 |
| Oct 6, 2025 | Moore David Scott · director | A-Award | 30,000 | $7.04 |
| Jul 1, 2025 | Thompson Peter A. · director, 10 percent owner: | Sale | 1,176,332 | $4.16 |
| Jul 1, 2025 | ORBIMED ADVISORS LLC · director, 10 percent owner: | Sale | 1,176,332 | $4.16 |
| Jun 16, 2025 | CLARK IAN T · director | A-Award | 15,000 | $4.24 |
| Jun 16, 2025 | Grais Linda · director | A-Award | 15,000 | $4.24 |
| Jun 16, 2025 | Morrison Scott W · director | A-Award | 15,000 | $4.24 |
| Jun 16, 2025 | Thompson Peter A. · director, 10 percent owner: | A-Award | 15,000 | $4.24 |
| Jun 6, 2025 | Jones William Benton · officer: See Remarks | M-Exempt | 19,357 | $3.50 |
| May 9, 2025 | MILLER RICHARD A MD · director, officer: President and CEO | M-Exempt | 559,073 | $3.50 |
| Apr 9, 2025 | van den Broek Richard · director | A-Award | 30,000 | $2.82 |
| Dec 23, 2024 | LEA LEIV · officer: Chief Financial Officer | A-Award | 300,000 | $4.99 |
| Dec 23, 2024 | MILLER RICHARD A MD · director, officer: President and CEO | A-Award | 750,000 | $4.99 |
| Dec 23, 2024 | Arcara Jeffrey · officer: Chief Business Officer | A-Award | 50,000 | $4.99 |
| Dec 23, 2024 | Jones William Benton · officer: See Remarks | A-Award | 300,000 | $4.99 |
| Jun 17, 2024 | Grais Linda · director | A-Award | 15,000 | $2.12 |
Institutional positioning
13F filings over the trailing two quarters
New 109Increased 131Reduced 70Sold out 30
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ORBIMED ADVISORS LLC | Unchanged | 7,165,006 | Aug 14, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 7,165,006 | May 15, 2026 |
| BlackRock, Inc. | Increased | 7,138,811 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 6,160,422 | May 13, 2026 |
| STATE STREET CORP | Increased | 4,474,091 | Aug 7, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 3,789,126 | Aug 14, 2026 |
| STATE STREET CORP | Increased | 3,565,992 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 3,292,710 | Aug 13, 2026 |
| ADAMS STREET PARTNERS LLC | Unchanged | 3,275,616 | Aug 14, 2026 |
| ADAMS STREET PARTNERS LLC | Unchanged | 3,275,616 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 3,234,538 | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 2,917,300 | May 15, 2026 |
| Vivo Capital, LLC | Unchanged | 2,805,816 | Aug 14, 2026 |
| VIVO CAPITAL, LLC | Increased | 2,805,816 | May 20, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 2,731,632 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 15, 2026